Scorpius And U.S. Biotech Partners For Future Biomanufacturing

Scorpius Holdings, Inc., a biomanufacturing company, has revealed a new strategic partnership with a U.S.-based biotech firm. Through this collaboration, the biotech company will work closely with Scorpius' program management team to transfer a research cell bank (RCB) to Scorpius' cutting-edge facilities in San Antonio, TX, where it will be used for future biomanufacturing operations.

Jeff Wolf, CEO of Scorpius, said in a statement, “This partnership underscores Scorpius' ability to support biotech companies at every stage of their journey, from innovative research to clinical trials. We are seeing a growing number of biotech companies seeking U.S.-based biomanufacturing partners, and Scorpius is equipped to provide early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs.”

He also mentioned, “Our clients highlight our flexibility and responsiveness—qualities often lacking in larger multinational CDMOs. With this partnership, we continue to fulfill the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research.”